EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Microbiome Engineering for Biotherapeutic in Alzheimer’s Disease Through the Gut–Brain Axis: Potentials and Limitations

Editha Renesteen iD, Jacqueline L Boyajian, Paromita Islam iD, Amal Kassab, Ahmed Abosalha iD, Stephanie Makhlouf, Madison Santos iD, Hongmei Chen, Cedrique Shum-Tim, Satya Prakash

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26115351 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Editha Renesteen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Technology and Cell Therapy Research Laboratory, Department of Biomedical Engineering, Faculty of Medicine and Health Sciences, McGill Uni…. Hauptthemen laut MEDLINE: Alzheimer Disease, Brain-Gut Axis, Gastrointestinal Microbiome, Biological Therapy. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 154 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Indonesia Endowment Fund for Education from the Ministry of Finance of the Republic of Indonesia, Fonds de Recherche du Québec - Santé (FRQS).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer’s disease (AD) is a neurodegenerative condition characterized by considerable cognitive decline and functional impairment, primarily due to the progressive alteration of neurons, microglia, and astrocytes. Pathological manifestations of AD include the loss of synaptic plasticity, reduction in synaptic strength by amyloid-beta, aggregation, and neurotoxicity from tau protein post-translational modifications, all contributing to the disruption of neural networks. Despite its current pharmacological treatment for AD, different approaches to treat such disease are being developed, from a microbiome perspective. The microbiome encompasses a diverse microorganism, including beneficial bacteria that create a positive impact to diminish AD pathogenesis. Growing evidence suggests that probiotic, prebiotic, synbiotic, and postbiotics can positively modulate the gut–brain axis, reducing systemic inflammation, restoring neurotransmitter balance, and improving gut health, thereby possibly mitigating AD pathogenesis. Moreover, there is paraprobiotics as the most recently developed biotherapeutic with beneficial effects. This review explores the correlation between AD and gut–brain axis as a novel biotherapeutic target. The underlying mechanism of the microbiota–gut–brain axis in AD is examined. Novel insights into the current applications as potential treatment and its limitations are highlighted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseBrain-Gut AxisGastrointestinal MicrobiomeBiological TherapyAnimalsHumansProbioticsSynbiotics

Stichwörter der Autor:innen

Alzheimer’s diseasegut–brain axisneuronprebioticprobioticsynbiotic

Autor:innen und Institutionen

  • Biomedical Technology and Cell Therapy Research Laboratory, Department of Biomedical Engineering, Faculty of Medicine and Health Sciences, McGill University, Montréal, QC H3A 2B4, Canada.
  • Pharmaceutical Technology Department, Faculty of Pharmacy, Tanta University, Tanta Al-Geish St., The Medical Campus, Tanta 31527, Egypt.

ORCID-Profile: Editha Renesteen, Paromita Islam, Ahmed Abosalha, Madison Santos

Förderung

  • CIHR
  • Indonesia Endowment Fund for Education from the Ministry of Finance of the Republic of Indonesia
  • Fonds de Recherche du Québec - Santé (FRQS)
  • Islamic Development Bank Scholarship
  • The Ministry of Higher Education of the Arab Republic of Egypt
  • Canadian Graduate Scholarship-Masters from the Natural Sciences and Engineering Research Council (NSERC)
  • Canadian Institute of Health Research
  • Ministry of Finance of the Republic of Indonesia

Zitieren

APA

Renesteen, E., Boyajian, J. L., Islam, P., Kassab, A., Abosalha, A., Makhlouf, S., Santos, M., Chen, H., Shum-Tim, C., & Prakash, S. (2025). Microbiome Engineering for Biotherapeutic in Alzheimer’s Disease Through the Gut–Brain Axis: Potentials and Limitations. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26115351

Vancouver

Renesteen E, Boyajian JL, Islam P, Kassab A, Abosalha A, Makhlouf S, et al. Microbiome Engineering for Biotherapeutic in Alzheimer’s Disease Through the Gut–Brain Axis: Potentials and Limitations. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26115351

BibTeX
@article{Renesteen2025,
  author = {Renesteen, Editha and Boyajian, Jacqueline L and Islam, Paromita and Kassab, Amal and Abosalha, Ahmed and Makhlouf, Stephanie and Santos, Madison and Chen, Hongmei and Shum-Tim, Cedrique and Prakash, Satya},
  title = {Microbiome Engineering for Biotherapeutic in Alzheimer’s Disease Through the Gut–Brain Axis: Potentials and Limitations},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26115351}
}
Kostenlos starten →